Skip to main content
Premium Trial:

Request an Annual Quote

Rheos Medicines, PatientsLikeMe Partner on Immune-Mediated Disease Research

NEW YORK — Autoimmune disease drug developer Rheos Medicines said on Thursday that it has partnered with PatientsLikeMe to support its research into the metabolic drivers of immune-mediated diseases.

Rheos said it will combine de-identified data from PatientsLikeMe's now-ended DigitalMe biomarker discovery program, which collected molecular and other biological data from thousands of participants, with multi-omics data from its own patient samples.

Analyzing these data will bolster its efforts to define patients most likely to respond to different therapies, Rheos said, and identify novel drug targets for immune-mediated diseases such as rheumatoid arthritis and lupus.

The Cambridge, Massachusetts-based companies will also work together to expand Rheos' access to additional patient samples, exploring new ways to engage patients.

Additional terms of the deal were not disclosed. 

"Our strategic collaboration with PatientsLikeMe represents an important opportunity to reach patients while further exploring the metabolic pathways that contribute to factors that promote chronic inflammation," Rheos CEO Barbara Fox said in a statement.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.